LENEXA, Kan.-CyDex Pharmaceuticals, Inc. today announced that Chief Executive Officer Dr. Theron Odlaug will present an overview of the Company at the upcoming BIO International Convention on Tuesday, May 19, 2009 at the Georgia World Congress Center in Atlanta.
Dr. Odlaug will update the business audience on the current development of the Company with emphasis on its transition from drug delivery to a specialty pharmaceutical company. He will track the progress which began with the novel, proprietary Captisol® technology, one of a series of anionically charged sulfobutyl ether β-cyclodextrins (SBE-CDs) that were originally synthesized and patented by scientists from the University of Kansas Higuchi Biosciences Center.
“Our current focus is on developing a portfolio of Captisol-enabled® new medications for which we intend to pursue FDA registration and commercialization directly,” said Dr. Odlaug. “We currently are seeking partners interested in combining their compounds and drugs with Captisol to enable creation of new products by significantly improving the solubility, stability, bioavailablity, safety and dosing of active pharmaceutical ingredients (APIs).
“We look forward to presenting an overview of our Company to the biotechnology business and scientific community at the BIO International Convention, and meeting with our colleagues to learn new ways our technology can be applied to meet worldwide unmet needs in healthcare. The large combined business and scientific audience that participates in BIO International is an ideal forum for CyDex.”
No comments:
Post a Comment